Literature DB >> 34752753

Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy.

Paul Yenerall1, Ralf Kittler2, John Minna3.   

Abstract

EGFR oncogenic mutations predict sensitivity to EGFR inhibitors in NSCLC, but less is known about EGFR "variants of unknown significance." Using preclinical models, 3D structure analyses, and patient response data, Robichaux et al. show in Nature that mutations in structural regions of EGFR predict responses to different EGFR inhibitors.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34752753      PMCID： PMC9241337          DOI： 10.1016/j.ccell.2021.10.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  10 in total

1.  Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Authors:  Takayuki Kosaka; Junko Tanizaki; Raymond M Paranal; Hideki Endoh; Christine Lydon; Marzia Capelletti; Claire E Repellin; Jihyun Choi; Atsuko Ogino; Antonio Calles; Dalia Ercan; Amanda J Redig; Magda Bahcall; Geoffrey R Oxnard; Michael J Eck; Pasi A Jänne
Journal:  Cancer Res       Date:  2017-03-31       Impact factor: 12.701

2.  Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.

Authors:  Jacqulyne P Robichaux; Yasir Y Elamin; Zhi Tan; Brett W Carter; Shuxing Zhang; Shengwu Liu; Shuai Li; Ting Chen; Alissa Poteete; Adriana Estrada-Bernal; Anh T Le; Anna Truini; Monique B Nilsson; Huiying Sun; Emily Roarty; Sarah B Goldberg; Julie R Brahmer; Mehmet Altan; Charles Lu; Vassiliki Papadimitrakopoulou; Katerina Politi; Robert C Doebele; Kwok-Kin Wong; John V Heymach
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

3.  COSMIC-3D provides structural perspectives on cancer genetics for drug discovery.

Authors:  Harry C Jubb; Harpreet K Saini; Marcel L Verdonk; Simon A Forbes
Journal:  Nat Genet       Date:  2018-09       Impact factor: 38.330

4.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes.

Authors:  Alexandre Melnikov; Peter Rogov; Li Wang; Andreas Gnirke; Tarjei S Mikkelsen
Journal:  Nucleic Acids Res       Date:  2014-06-09       Impact factor: 16.971

Review 6.  Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.

Authors:  Alessandro Russo; Tindara Franchina; Giuseppina Ricciardi; Alessandra Battaglia; Maria Picciotto; Vincenzo Adamo
Journal:  Int J Mol Sci       Date:  2019-03-21       Impact factor: 5.923

7.  Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology.

Authors:  Fanny S Krebs; Vincent Zoete; Maxence Trottet; Timothée Pouchon; Christophe Bovigny; Olivier Michielin
Journal:  NPJ Precis Oncol       Date:  2021-03-18

8.  Structure-based classification predicts drug response in EGFR-mutant NSCLC.

Authors:  Jacqulyne P Robichaux; Xiuning Le; R S K Vijayan; J Kevin Hicks; Simon Heeke; Yasir Y Elamin; Heather Y Lin; Hibiki Udagawa; Ferdinandos Skoulidis; Hai Tran; Susan Varghese; Junqin He; Fahao Zhang; Monique B Nilsson; Lemei Hu; Alissa Poteete; Waree Rinsurongkawong; Xiaoshan Zhang; Chenghui Ren; Xiaoke Liu; Lingzhi Hong; Jianjun Zhang; Lixia Diao; Russell Madison; Alexa B Schrock; Jennifer Saam; Victoria Raymond; Bingliang Fang; Jing Wang; Min Jin Ha; Jason B Cross; Jhanelle E Gray; John V Heymach
Journal:  Nature       Date:  2021-09-15       Impact factor: 69.504

9.  Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

Authors:  Jang Ho Cho; Sung Hee Lim; Ho Jung An; Ki Hwan Kim; Keon Uk Park; Eun Joo Kang; Yoon Hee Choi; Mi Sun Ahn; Myung Hee Lee; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  J Clin Oncol       Date:  2019-12-11       Impact factor: 44.544

10.  Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.

Authors:  Paul Yenerall; Rahul K Kollipara; Kimberley Avila; Michael Peyton; Christopher A Eide; Daniel Bottomly; Shannon K McWeeney; Yan Liu; Kenneth D Westover; Brian J Druker; John D Minna; Ralf Kittler
Journal:  Cancer Res       Date:  2021-07-23       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.